Quinacrine and derivatives thereof for treatment of viral infections
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorDaekyu Sun
Life of this patent
Estimating the term…
Abstract
Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The present invention reveals that quinacrine directly binds to G4 RNAs found in genomic RNA of the COVID-19 virus, showing antiviral activity against COVID-19 using in vitro cell culture systems. An object of the present invention is thus a new pharmaceutical composition of quinacrine for the treatment of COVID-19. Another object of the invention is a method for administering quinacrine by various routes specifically for treatment, including oral administration, sterile intravenous injection, and others.
Claims26
-4. (canceled)
A method of preventing or treating a viral respiratory infection in a subject in need of such treatment, the method comprising administering to the subject a therapeutic amount of quinacrine or a derivative thereof.
-9. (canceled)
-14. (canceled)
(canceled)
-21. (canceled)
A composition comprising a derivative of quinacrine:
-50. (canceled)
Dependencies are inferred from the claim text.